Breaking News Instant updates and real-time market news.
2018-10-18 14:35:48
SBPH
Spring Bank Pharmaceuticals
$14.43
0.05 (0.35%)
14:35
10/18/18
10/18
14:35
10/18/18
14:35
Adage Capital reports 6.18% passive stake in Spring Bank Pharmaceuticals
19
Oct
27
Nov
SBPHSpring Bank Pharmaceuticals
$14.43
0.05 (0.35%)
02/21/18
RILY
02/21/18 NO CHANGETarget $30 RILY Buy
Spring Bank remains undervalued hepatitis B play, says B. Riley FBR
B. Riley FBR analyst Madhu Kumar reiterates a Buy rating on Spring Bank Pharmaceuticals with a $30 price target following the company's Q4 results. The analyst says the company remains an undervalued mid-stage hepatitis B therapy play.
08/03/18
JMPS
08/03/18 NO CHANGETarget $20 JMPS Outperform
Spring Bank's early inarigivir data 'promising,' says JMP Securities
After Spring Bank Pharmaceuticals reported data on the third cohort in the Phase 2 ACHIEVE trial of inarigivir in HBV patients that met the primary endpoints, safety and antiviral activity, at both week 12 and week 24, JMP Securities analyst Liisa Bayko called the early data "promising." She thinks inarigivir has the potential to be an "integral piece to many iterations of combinations," which could "put the company in play" if the evidence builds. Bayko reiterated her Outperform rating and $20 price target on Spring Bank shares.
08/14/18
PIPR
08/14/18 INITIATIONTarget $25 PIPR Overweight
Spring Bank Pharmaceuticals initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Spring Bank Pharmaceuticals with an Overweight rating and $25 price target. The company has reported "encouraging" proof-of-concept data from the first three cohorts of the Phase II study of monotherapy inarigivir, in development to treat hepatitis B virus infection, Tenthoff tells investors in a research note. The analyst sees inarigivir as the "essential" immunomodulatory component in combination therapy to achieve an HBV functional cure.
10/09/18
JEFF
10/09/18 INITIATIONTarget $28 JEFF Buy
Spring Bank Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Spring Bank Pharmaceuticals with a Buy rating and $28 price target. The company is developing inarigivir for hepatitis B virus and the drug is "de-risked" given its dose response and "excellent" safety profile, Raycroft tells investors in a research note. He believes inarigivir "could position as a backbone now and for the longer-term" in HBV treatment.